New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 26, 2012
10:00 EDTPG, PSX, MYL, CME, ACAT, OI, HBAN, AB, LAZ, TGT, STEL, EXPEOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AllianceBernstein (AB) upgraded to Equal Weight from Underweight at Morgan Stanley... CME Group (CME) upgraded to Outperform from Market Perform at Raymond James... Expedia (EXPE) upgraded to Buy from Hold at Benchmark Co.... Expedia (EXPE) upgraded to Outperform from Market Perform at Raymond James... Huntington Bancshares (HBAN) upgraded to Buy from Neutral at Citigroup... Mylan (MYL) upgraded to Buy from Hold at Canaccord... StellarOne (STEL) upgraded to Strong Buy from Outperform at Raymond James... Owens-Illinois (OI) upgraded to Buy from Neutral at BofA/Merrill... Phillips 66 (PSX) upgraded to Outperform from Neutral at Credit Suisse... Target (TGT) upgraded to Buy from Neutral at Buckingham... Arctic Cat (ACAT) upgraded to Strong Buy from Buy at Felti... Proctor and Gamble (PG) upgraded to Outperform from Underperform at CLSA... Lazard (LAZ) upgraded to Neutral from Sell at Rochdale.
News For AB;CME;EXPE;HBAN;MYL;STEL;OI;PSX;TGT;ACAT;PG;LAZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
July 23, 2015
08:33 EDTMYLMylan foundation says shareholders at risk of Teva takeover
Subscribe for More Information
07:45 EDTHBANHuntington Bancshares releases results of 2015 Dodd-Frank Stress Test
Subscribe for More Information
07:03 EDTLAZLazard reports Q2 adjusted EPS 98c, consensus 77c
Subscribe for More Information
06:58 EDTHBANHuntington Bancshares reports Q2 EPS 23c, consensus 21c
Subscribe for More Information
July 22, 2015
15:26 EDTHBANNotable companies reporting before tomorrow's open
Subscribe for More Information
10:06 EDTMYLAbbott CEO says supportive of Mylan pursuit of Perrigo
Subscribe for More Information
09:30 EDTMYLAbbott CEO says 'pretty alligned' with Mylan so far
08:38 EDTTGTNRF cuts 2015 retail sales growth forecast to 3.5% from 4.1%
Subscribe for More Information
06:34 EDTACATArctic Cat says focus is to rebuild, reposition company for 2017
The company commented, “As we’ve said, our focus over the next year is to rebuild and reposition the company for a return to long-term growth in fiscal 2017 and beyond. To achieve this, a key priority remains rightsizing our core North America ATV dealer inventory levels during fiscal 2016. We believe that we have strong strategic plans to turn the business around. Our strong balance sheet gives us the flexibility to make investments to grow the business through innovative products, strategic and OEM partnerships, and bolt-on acquisitions. Although we face significant challenges in fiscal 2016, including continued foreign currency headwinds, we see tremendous opportunities to improve the company’s operations, expand gross margins and enhance financial performance over time. We are excited about Arctic Cat’s long-term future.”
06:34 EDTACATArctic Cat backs FY16 EPS 80c-95c, consensus 90c
Subscribe for More Information
06:32 EDTACATArctic Cat reports Q1 EPS (8c), consensus 0c
Subscribe for More Information
July 21, 2015
10:01 EDTPGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:43 EDTCMECME Group, MCX of India sign MOU
CME Group, the world's leading and most diverse derivatives marketplace, and Multi Commodity Exchange of India, or MCX, India's leading commodity exchange, today signed a Memorandum of Understanding, or MOU, on various cooperation activities and potential business opportunities, including a joint viability study of setting up operations in an International Finance Service Center in India. Under this MOU, various initiatives between CME Group and MCX will also include the establishment of a joint working group to explore opportunities to develop and market new products and services for the US and Indian markets, as well as collaboration on customer education. At the same time, CME Group and MCX also announced the extension of the licensing agreement which enables MCX to settle their rupee-denominated oil and gas contract to CME Group's NYMEX prices.
July 20, 2015
16:36 EDTPGProcter & Gamble initiated with a Neutral at Sterne Agee CRT
Subscribe for More Information
13:46 EDTTGTAmazon seen eclipsing Macy's as top U.S. clothing retailer
Subscribe for More Information
08:38 EDTMYLAnalyst predicts Zoetis merges with Bayer unit, not Valeant
Zoetis (ZTS) in recent months has been the subject of takeover speculation, possibly for Valeant (VRX), but a Jefferies analyst told investors today in a research note that he views a deal with a unit of healthcare giant Bayer (BAYRY) as "highly likely" for the animal medicine company. BACKGROUND: Bill Ackman of Pershing Square, who owns stakes in both Zoetis and Valeant, said in early May while speaking on CNBC that Zoetis is a "great” business on a standalone basis, but he also spoke of the company's strategic value. Ackman added, however, that he was "not sure" that Valeant was the best acquirer of Zoetis. Subsequently, in late June, The Wall Street Journal reported that Valeant made a preliminary approach regarding a potential deal to buy Zoetis. CNBC's David Faber said the next day, citing his own sources, that Valeant reached out to Zoetis as a courtesy to common shareholder Ackman and was unlikely to pursue an acquisition of the company, though he cautioned then Valeant could change its approach and pursue a deal. BAYER: Jefferies analyst Jeffrey Holford said in a note today that he views a tie-up between Zoetis and Bayer's Animal Health business in 2016 as "highly likely." He sees Mylan's (MYL) acquisition of Abbott's (ABT) non‑U.S. developed markets specialty and branded generics business as a potential proxy for how a transaction could be structured, adding that such a "spinversion" could achieve up to 36% long-term earnings accretion for Zoetis. Holford reiterated a Buy rating on Zoetis with a $60 price target, while downgrading Bayer to Hold, citing valuation following the recent outperformance of its shares. IDEXX: While being discussed as a target, some analysts have also opined on companies that Zoetis could pursue as a buyer. On June 29, Canaccord said that in investor meetings with IDEXX (IDXX) executives declined to comment on Zoetis' potential interest in scaling up its animal health diagnostics business. Canaccord added that it thought Zoetis could make a bid for IDEXX. The firm reiterated its Buy rating and $80 price target on IDEXX shares at that time. PRICE ACTION: Since June 25, the day the Journal first reported on Valeant's preliminary takeover approach to Zoetis, the animal health company's shares have dropped nearly 4%. Zoetis closed down 20c to $47.80 on Friday.
07:33 EDTMYLInternational AIDS Society to hold a conference
Subscribe for More Information
07:30 EDTMYLZoetis 'highly likely' to merge with Bayer unit in 2016, says Jefferies
Subscribe for More Information
July 19, 2015
18:13 EDTTGTMacy's considered, rejected sale/lease-backs in past, WSJ says
Macy's (M) executives have considered sale/lease-backs "over the years" and have come to negative conclusions, reports the Wall Street Journal, citing people familiar with the company. The report comes in the wake of Starboard Value pressuring Macy's to spin off its real estate, and sources said the activist investor sees several options, including a REIT, a Hudson’s Bay’s-style real estate partnership, a sale/lease-back, or borrowing money against the properties. Separately, a source said Target (T) is still reluctant to relinquish control over its real estate. Reference Link
13:37 EDTPGProcter & Gamble shares look unattractive, Barron's says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use